Blog

A few general points

A

I have recieved Prof Bakshi’s interview via email. However i have yet to write to him and get his approval to forward the interview. In the meantime i have recieved a huge number of requests for forwarding the interview. I will try to email to all who have requested it (if prof bakshi is fine with it) , but please bear with me as the number of requests is huge.

I also recieve personal emails several times. I have attempted to answer them but i am not able to do justice to all of them due to personal time constraints. Hope those of you who do not hear me, will understand that i am time constrained and hence may not be able to reply some times. Leaving a comment would be a good idea in such a case. Some other reader on the blog may be able to respond to your query equally well.

Finally if you wish to subscribe to the blog via email , please enter your email id above the blog archives. You will recieve an email update whenever i post a new post.

Please feel free to leave a comment on how to improve the blog further and make it more useful.

Searching for investment candidates – II

S

I have posted earlier a list of investment candidates which had passed through my investment filters. After doing a quick 20-30 min analysis, I slotted these ideas into the ‘Go’ bucket which are good for further analysis and into the ‘No-go’ bucket which are the rejected ideas.

A few more ideas in each bucket follows –

No Go bucket

Pricol – An auto ancillary midcap company. Topline has grown by 50% in the last 5 years and net profit has doubled in the same time. ROE is firmly above 20% and the valuation seems to be cheap at a PE of around 7-8. However the company has a high debt of almost 230 crores (DE ratio is more than 1 ) and the cash flow is poor too. Debtors have gone up by 400% and inventory has doubled too. The quality of earnings seem to be poor. I would this company a pass for the time being.

Navneet publications – A publishing company. The topline and bottomline has been stagnant for quite some time. The balance sheet does not look too good with inventories up 4 fold in the same period. The ROE and other numbers such as margins and debt equity ratio seem to be fine. However the free cash flows seem to be poor and the performance is erratic. Although the company seems to have some competitive advantage, the performance in the past has not been very good. Would give this company a pass.

Go bucket

Sarla polyester – A small cap company into textile processing. The turnover has grown from 30 Crs to 88 Crs in 2006. The netprofit has gone up to almost 11 Crs and this year could be almost 13-14 Crs. The company has a very low debt of 8-9 crs on books and a high ROE of 20%+. The valuations are fairly low at a PE of 6-7. Definitely worth a closer look

Investment and precision casting – A small cap casting and forging company. The net revenue has tripled in the last 5 years and the net profit has also tripled in the same period. Net margins have held steady at 15% and the ROE is 20%+. The company has a low debt partly offset by cash balance. The current year profit seems to be flat at 8 Crs and the valuation seem reasonable at 10 times current year earnings. Worth a closer look.

Searching for investment candidates – I

S

Recently I shortlisted a few stocks which passed through the basic filters and did a quick 15-20 min analysis to sort them into two buckets – the ‘go bucket’ and ‘No go bucket’. The ‘no go bucket’ are the rejected stocks on which I will not be spending any more time for further analysis. I may have rejected some stocks which may turn out to be good ideas later, but I prefer the sin of ommision than commision. The ‘Go bucket’ has stocks which have to go through more detailed analysis before I commit money to them.

No Go bucket

Torrent pharma – A profitable pharma company into bulk drugs and formulations. Growing well and has a clean balancesheet. Have not looked into detail, but the valuation seems to be around 15-16 times latest earnings. Have scanned the financials very briefly and cannot find anything wrong. However it is in the No go bucket as the valuations are not too cheap. May come back later after I run out of ideas.

Diamines and chemicals – This is a very small company with turnover of 20-25 Crs and Net profit in the current year of 6-7 Crs. It sells for a market cap of 35 Crs and so it seems to be very cheap at a PE of around 6. The company had a negative networth till 2003 and seems to have turn around since then. Has a high Debt equity ratio of almost 0.7. Although looks cheap, I am not comfortable due to the small size of the company and inconsistent operating history. No further analysis on this company.


Go bucket

Poly medicure – A health care company into health care disposables. Currently growing in double digits with this years topline likely to be around 80-85 Crs and net profit to be between 7-8 Crs. The ROE is 20% plus range and the entire company is selling at around 75 Crs, with a PE of around 8. Had a brief look at their website and was unimpressed. No annual report or financial available on the company website. Worth further investigation for the time being

Ultramarine and pigments – A small company into dyes and pigments with an annual turnover of around 60-70 Crs which has been stagnant for the last 4-5 years. Net profits have zoomed from 4 Cr to almost 18 Crs (expected) for the current year. Capital invested in the business has come down in the meantime with investments on the balance sheet of around 25 Crs (FY 2005) and low debt of around 5 Crs. Capital requirements in the business seem to be low and hence the business seems to have good free cash flow and a return on invested capital of almost 50%. Definitely worth a closer look.

next post : i would be listing more ideas in both the buckets

ps : Please see my disclaimer. I would not want anyone to lose money based on my analysis

A must read interview by prof bakshi

A

I admire prof. Bakshi, have read all his articles and read his blog regularly. He is a great teacher and it would have been great if I had been his student. I found this interview on capital ideas online. Unfortunately only part of the interview is available and the rest is available only to subscribers.

I would recommend reading the interview. On reading the section under cash bargains, I was almost nodding my head in agreement. I have posted a few cash bargains like novartis, cheviot company and merck earlier. I plan to re-read security analysis by benjamin graham and further expand the scope of my search for investment ideas.

In addition, my own thinking has started expanding to include graham type situations more. The reason is that buffett type companies are diffcult to find and require a lot of indepth understanding of the business to make a meaningful investment. Looking back at my stock screens, I realise that I left a lot of bargains on the table because they were mediocore businesses. These businesses were selling below intrinsic value and although the intrinsic value did not expand, a convergence of the current price with intrinsic value yielded good results.

A move to expand into graham type stocks has increased the number of my investment ideas. However this type of investing means a higher portfolio turnover and a constant search for cheap stocks as one may not be able to buy a great company at a decent price and enjoy the benefits of an increase in the instrinsic value.

This does not mean that I am not looking for the buffett type good companies. It is just that I am trying to let go of my mental blocks to other types of companies and other types of investing. Who knows I may overcome my aversion to trading too 🙂

A request – If any one reading this post has access to the full interview, I would request you to email me the link or the interview itself (id : rohitc99@indiatimes.com)

update : 4th june : i have recieved the complete interview by email. thanks to sajeesh mathew for that. It is a great interview and i learnt a lot from it. I will have to confirm with sajeesh and prof bakshi if it fine to email the interview to others. I would definitely not be posting it

Value in midcaps ?

V

I have written earlier that there seems to be more value in the midcap space than Large caps represented by the Sensex and Nifty. The above hypothesis came about as I am finding far more ideas in the midcap than the large cap sector of the market.

I decided to check the above hypothesis and generated the above two charts for the Nifty index and CNX midcap. The nifty index has appreciated by around 23% in the last year, whereas the midcap index has increased by around 13 %. Does this prove my hypothesis. Yes and no !. Yes because some of the stocks have come down quite a bit and may be worth investing. No, because the midcap index as a whole is not too cheap, currently trading at around 17 times PE.

So blindly buying into the index may not make sense, but picking specific stocks would.

Based on the above view I tried to look for some mutual funds in the midcap space and found the following interesting. I am listing the negatives of each of the funds. The returns of the funds have been fine and they may be worth a look

Birla midcap – This is a 5 star fund. It does not have a very long operating history. The fund has been around 3 years and the last 2 years performance has not been great

Sundaram mid cap – This fund has delivered good performance in the long run. However the last 1 year performance has not been great. Also the fund has a new fund manager. The fund is extremely spread out and has more than 70-80 stocks in the portfolio

Franklin prima fund – This fund has the longest operating history. It has done well in the past and the fund manager has been around from the beginning. The manager follows a buy and hold philosophy and has higher portfolio concentration. The last 3 year performance has been average though.

As usual, the fund expenses are high and the volatility of these funds is also high. An SIP mode of investment may be a good approach.

In addition, funds like HDFC equity and Franklin prima plus have a diversified approach and can move between various caps. These funds may also be good way of investing in the mid-cap space too as HDFC equity has around 50% exposure midcaps and Franklin prima plus has around 35-40% exposure to midcaps.

You can look for the details for each fund at valueresearchonline.com. I am not recommending any of the above funds, just laying out the facts for some funds which I find worth investigating further in the midcap space. A superior approach would be to pick specific stocks, but that requires a higher amount of effort and time.

Red flags – Aftek infosys

R

Aftek infosys appeared on my stock screens a few days back. I also had a comment from prem sagar on the company. The company seems to be extremely undervalued. It seems to have almost 400 Crs of cash on the books with a market cap of just around 650-700 Crs. With the last year profits of 98 crs, the company seems to be selling at a PE of 2-3. On the face of it the company seems to be an investors wish come true. My initial scan showed nothing wrong, so I decided to dig deeper and came up with a can of worms.

– the company’s management was penalized by SEBI for participating with Ketan parekh in various behind the scene deals during the 2000 bull market (see here)

– The company had an investment of almost 46 Crs in a company called Arexera. They have accquired this company this year (the balance portion) for a sum of 56 crs. One would consider this accquisition to be significant. The positives of the acquisition are mentioned all over the report. However the valuation of the deal is not mentioned. The company had a net profit of 1 Crs last year (see page 100 of the annual report). The company was acquired at a valuation of 100 Crs ( PE = 100 !!!). The management has not discussed the valuation anywhere in the report and why they paid so much for it. Finally surprise , surprise – this company was accquired from the promoters !!! . See the cash flow statement on page 83. There is an entry for 54.8 Crs which was paid to promoters to acquire this company. So the management accquires this company and has a related party transaction and does not mention this in the complete report??

– The company has issued 3.96 lac warrants to the promoters. They have received 10% of the price now and the rest can paid by the promoters within 18 months. Why have these warrants been issued if the company is swimming in cash, had some FCCB still open and is making almost 100 Crs per year ?

– Promoter holding is only 12%.

– FCCB issue in the last few years to raise capital. This capital is being used to accquire companies like Arexera from promoters.

The stock may do well (had a jump of 10 % recently). However I have bad feel of the whole thing. All the red flags I have pointed above don’t give me any confidence in the management. I still think the business will do well and the company should make money. But I am not sure if the shareholders will benefit or the promoters would. Their past and current actions don’t give me any confidence. I am definitely giving the stock a pass although there could be some trading gains to be made.

Analysis of Novartis india

A

Novartis india is the Indian subsidiary of Novartis AG. The company has the following business segments – Pharmaceuticals, Generics, OTC and Animal care.

The company is in various therapeutic areas such as Immunology and Transplantation, Oncology, Gynaecology, Central Nervous System, Respiratory, Pain and Inflammation, Ophthalmics and Orthopaedics. In the OTC space the company has some strong brands such as Sandoz.

Financials

The company has just tread water in the last few years. The topline growth has been more or less flat and is currently at around 520 Crs. The bottom line is now at around 88 Crs. Both the topline and bottomline have growth a low single digit growth rates and I expect the same to continue.

The Global parent has a local unlisted subsidiary and has made comments of introducing products through the unlisted subsidiary. As a result the topline and bottomline growth for novartis could be at best 5-7% per annum for the next few years. The poor growth in the last few years has mainly been due to poor performance of generics, sale of the Rifampicin (anti-TB) business and due to price control on some of its brands.

Valuation

At the current profit of 88 Crs and EPS of around 27.5, the company sells for around 12-13 times PE. In addition the ROE and ROCE is actually very high. The 2006 AR shows that the company as just 10 Crs in fixed assets and negative working capital. As a result the Return on capital is very high (>100%). All the assets are in cash or inter corporate deposits and other liquid investment.
It seems the company has become complete asset free and is outsourcing almost its entire production.
In addition in one of the earlier AGM, the company has mentioned that the excess profits would be returned via generous dividends. The dividends for the last few years have been 200%+ giving a dividend yield of almost 3-4%.

On a comparable valuation basis, the other pharma MNC with similar business model sell at around 20-30 times PE.

Thus the stock appears undervalued with intrinsic value between 600-650 Rs

Risk

Poor topline and bottom line growth or even de-growth. In absence of few product launches in the Pharma segment and continued competition and price pressure the company could have a drop in net profits. The OTC and animal care business seem to be growing, but do not have very high margins
In addition the parent could increase the focus on the unlisted subsidiary and milk the listed one for profits.

Conclusion

The company is selling at a 4 year low. I feel that all the negatives seems to be priced in. Net of cash, the company sells at almost 8-9 times earnings or cash flow. This seems to be fairly low for a stable and profitable pharma business.

Business models of Pharma industry

B

I have written (see here) earlier on the pharma industry in 2005. A few high profile patent challenge losses in 2005 and 2006, brought down the valuations for several companies. My basic thoughts about the industry have not changed

I have been analysing the industry further recently and can see two different business models.

The Domestic market focussed model

Most MNC’s like novartis, merck, pfizer come under this model. The key characterisitics of the model are

1. Subsidiary of a global MNC operating in india for the last few decades
2. The subsidiary operates as an extension of the global company and due to the patent law in the past, has introduced mostly the off-patent drugs.
3. Strong brands, marketing network and good return on capital and strong competitive advantage.
4. Possibility of introducing the drugs from global portfolio. However in some cases the parent company has an unlisted subsidiary and hence treats the listed one as a cash cow. In such cases the market is rightly giving a lower PE multiple due to the poor corporate governance attitude of the parent.
5. Strong cash flows due to minimal R&D and very low assets in the business as most of the manufacturing is sub-contracted.
6. Low growth in domestic market, marked by constant price controls (DPCO and new pharma policy) by the government on various essential drugs. This has resulted in poor topline and bottomline growth for several companies solely dependent on the domestic market.

The International market focussed model

1. This model is followed by the indian pharma companies such as ranbaxy, dr reddy’s, nicholas pharma etc
2. These companies are in the process of globalizing. Their approach to it has been through the drugs which are coming off patent (generics strategy). These companies have built a strong R&D infrastructure in india to develop these drugs coming off patents. They also have a marketing and legal infrastructure in foreign markets to file ANDA and other applications for these drugs as soon as they come off patents. If these companies win these cases, then they get a 180 day exclusive marketing period for these drugs. Post the exclusive period too, these companies are able to maintain good market shares. Thus these companies have created a value chain of R&D labs in india, and a distribution, marketing and legal infrastructure abroad to funnel these new drugs coming off patents.
3. These companies are following riskier strategy as these legal challenges are costly and if the company loses one, the entire money is down the drain.
4. The market was pricing earlier as if each of these ‘bets’ would pay off. However due to some high profile failures in the past, the market has started pricing the risk of the strategy now.
5. Some companies are also acting as outsourcers for the global pharma companies. This is the contract or custom manufacturing business. There a large no. of FDA approved facilities in india ( second largest in the world). Several indian companies now provide advanced manufacturing facitility to global pharma companies and are now doing accquisitions in this space to accquire complementary assets abroad.
6. The third segment of this model is the R&D segment where some of the top companies are now investing heavily in R&D to develop NCE and NDDS. Some of the molecules are now in the stage I and Stage II trials. Some companies such as DRL have licensed these molecules to other companies and they get royalties based on milestones. This is a high risk, high return startegy. However it is likely the larger pharma companies in india could go down this path and emulate their global counterparts.

It is easier to predict the cash flow and valuation of the domestic model as the overall business risk is lower in that model. The international business model has a higher upside, however the valuation seems to reflect that upside in several instances. All these international market focussed model has ‘real options’ embedded in it. However I do not have the skill to do the valuation of these options. It is often difficult to predict which Patent challenges would be successful and which ones will fail

For additional detail on the pharma industry see here. The article is dated, but useful to understand the various terms such as ANDA, Para I,II etc.

There are several good stocks in the pharma industry available at reasonable valuations. I have discussed about merck earlier. In addition I am looking at novartis and alembic too.

Caution : Stocks which i look at generally perform poorly in the short term as they are undervalued. Please do your own research before investing in them.

How to be a better investor – evaluating performance

H

One of the most important aspects of becoming a better investor is to evaluate one’s performance. However I do not think an absolute performance is the right way to do it.

For ex: If one’s stock portfolio returned 2% during the period 2000- 2003, I would consider it to be a superior performance than a 30% increase from 2003-2006. The reason is that during the period 2000-2003 , the market lost more than 30%, whereas during the period 2003-2006 the market almost doubled.

I evaluate my own performance as follows

I use the following formulae to evaluate the performance on my stock portfolio. I am not referring to a single stock, but for the entire stock portfolio.

Return = End portfolio amount – starting portfolio amount – cash added (or removed)/ starting portfolio amount

The period for the above formulae can be a month, quarter or a year. I prefer to evaluate the performance annually.

I compare this performance with the following three benchmarks. You can look at these benchmarks as three rising levels of hurdles to be crossed.

Level 1 – No risk FD return – This is the return I get from investing in bank FD. The stock portfolio has to cross this level. Otherwise I am way better off investing in FD’s and going off to sleep.

Level 2 – Index fund return – This is the return one can get by investing in the index (NSE or BSE) via ETF’s or index funds. The stock portfolio has to outperform this level, other wise I am better off investing in an index fund.

Level 3 – Mutual fund return – I referred to it in my previous post. My stock portfolio return should exceed the return I get from my portfolio of mutual funds (post expenses). If not, then I am again better off handing my money to the fund managers and doing something better with my time.

A caveat – One should not make a decision based on a single year’s return. In a single year, the stock portfolio returns can be volatile and even be below level 1 benchmark . I prefer to look at rolling 3 year returns to reach some tentative conclusion. I would prefer to look at the results of atleast 5 years before reaching a conclusion that I have crossed each of the above benchmarks. For a 5 year period, one should look at the cumulative returns from the stock portfolio and compare it with the above 3 benchmarks. Only if one has done substantially better than the three benchmarks, can one conclude that he or she ‘may’ be a superior stock picker.

The above may sound harsh and pompish. But I think if one has to be better investor, honest appraisal of one’s performance is important. If I have five duds and my portfolio returns less than what I could get in an FD, then there is not much to be gained from a stock pick which doubled in 15 days. I may have bragging rights and may feel smart, but I am not being honest and objective about my performance.

How to be a better investor – My approach

H

I posted the reply from warren buffett on the above question. The key takeaway from his reply is that one should read a lot and invest your own money based on your ‘own’ ideas and analysis.

I will touch upon my approach to improve myself as an investor in this post.

I have been reading various investment related books, articles and annual reports for some time now. However my approach to it was disorganized and did not have any pattern to it. However in the last 2 years I have developed a plan to read with specific goals in mind.

I look at reading with two key objectives

1. Find new ideas (which are profitable)
2. Develop mental models to become a better investor (read this article from charlie munger on mental models)

I have broken the second objective into the following topics (related to investing)

Finance – topics such as Balance sheet, income statement, various ratios, analysis of these statements etc
Accounting – understand various accounting concepts and standards
Valuation
Competitive advantage and strategy
Probability and analysis of risk
Study of business models
Economics – mainly micro economics
Investing – value investing
Options, derivates and other financial instruments

I have better knowledge in some these areas relative to other topics. For example I have not read much on options and derivatives till date. Somehow I get put off by all the math in it (although I am engineer by background 🙂 ).

So at the beginning of the year I try to assess myself on these areas and try to identify the specific areas on which I would focus. For ex: I am currently focussing on topic 4 – competitive advantage. I identify books for this topic and add it to the list of books I would be reading over the course of the year. I run through all the topics in this manner and try to come up with a tentative book list for the year. This is not a list set in stone. If I find a better book for the topic I am interested in, I end up replacing it with that book.

In addition to the above book list, I have also listed the industry groups I would be focussing on this year. Currently my focus is on pharma. I have shortlisted around 5-6 industry groups for the year (see my industry analysis spreadsheet here). To improve my knowledge in a particular industry (related to topic 6), I read up on the annual reports of some of the top few companies in the industry. In addition, I try to read up on industry reports if I can get access to them for free.

This industry group analysis activity helps me in increasing my circle of competence and also helps me in coming up with new investment idea. Finally as all knowledge in investing is cumulative, I can easily use this knowledge again later to come up with good investment ideas.

Finally I run valuation screens and if I can get some undervalued candidates, I read up on them. This is more haphazard as I may get candidates in industries which I have no prior knowledge. However it is a good starting point in those cases. If the candidate is in an industry in which I have done some prior study, then the analysis is faster.

The last step is – as they say on shampoo labels – rinse and repeat. That is I keep repeating the above process. Ofcourse the books, the topics and the industry groups keep changing, but the approach is the same. This approach has been helpful as it keeps me focussed on areas which i need to improve and also to enhance my circle of competence

Subscription

Enter your email address if you would like to be notified when a new post is posted:

I agree to be emailed to confirm my subscription to this list

Recent Posts

Select category to filter posts

Archives